Corpus ID: 70701334

Tumor Necrosis Factor in Isolated Hepatic Perfusion: credits, debits and future directions

@inproceedings{Vries2003TumorNF,
  title={Tumor Necrosis Factor in Isolated Hepatic Perfusion: credits, debits and future directions},
  author={M. D. Vries},
  year={2003}
}
textabstractPatients with irresectable hepatic malignancies remain an intriguing clinical problem. Hepatocellular carcinoma (HCC) is the most common primary hepatic malignancy and approximately one million individuals will develop this tumor per year. The incidence of these tumors varies widely worldwide, being most common in the Far East [1]. Recent advances in the early detection of these tumors have improved the prognosis and long-term survival has been reported in patients with small… Expand

Figures, Tables, and Topics from this paper

References

SHOWING 1-10 OF 148 REFERENCES
Hepatic artery infusion for metastatic neoplastic disease.
  • 14
Isolated hepatic perfusion with tumor necrosis factor and melphalan for unresectable cancers confined to the liver.
  • 187
Resection of ‘recurrent’ colorectal metastases to the liver
  • 69
Rationale and indications for perfusion in liver tumors: Current data
  • 24
Role of tumor necrosis factor on toxicity and cytokine production after isolated hepatic perfusion.
  • T. Lans, D. Bartlett, +5 authors H. Alexander
  • Medicine
  • Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2001
  • 45
...
1
2
3
4
5
...